United States HIV Drugs Market Report by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist, Fusion Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033

United States HIV Drugs Market Report by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist, Fusion Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A20385

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   United States HIV Drugs Market - Introduction

    4.1    Overview
    4.2    Market Dynamics
    4.3    Industry Trends
    4.4    Competitive Intelligence
5   United States HIV Drugs Market Landscape
    5.1    Historical and Current Market Trends (2019-2024)
    5.2    Market Forecast (2025-2033)
6   United States HIV Drugs Market - Breakup by Drug Class
    6.1    Nucleoside Reverse Transcriptase Inhibitors
        6.1.1 Overview
        6.1.2 Historical and Current Market Trends (2019-2024)
        6.1.3 Market Forecast (2025-2033)
    6.2    Multi-Class Combination Products
        6.2.1 Overview
        6.2.2 Historical and Current Market Trends (2019-2024)
        6.2.3 Market Forecast (2025-2033)
    6.3    Protease Inhibitors
        6.3.1 Overview
        6.3.2 Historical and Current Market Trends (2019-2024)
        6.3.3 Market Forecast (2025-2033)
    6.4    HIV Integrase Strand Transfer Inhibitors
        6.4.1 Overview
        6.4.2 Historical and Current Market Trends (2019-2024)
        6.4.3 Market Forecast (2025-2033)
    6.5    Non-Nucleoside Reverse Transcriptase Inhibitors
        6.5.1 Overview
        6.5.2 Historical and Current Market Trends (2019-2024)
        6.5.3 Market Forecast (2025-2033)
    6.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist
        6.6.1 Overview
        6.6.2 Historical and Current Market Trends (2019-2024)
        6.6.3 Market Forecast (2025-2033)
    6.7    Fusion Inhibitors
        6.7.1 Overview
        6.7.2 Historical and Current Market Trends (2019-2024)
        6.7.3 Market Forecast (2025-2033)
    6.8    Others
        6.8.1 Historical and Current Market Trends (2019-2024)
        6.8.2 Market Forecast (2025-2033)
7   United States HIV Drugs Market - Breakup by Distribution Channel
    7.1    Hospital Pharmacies
        7.1.1 Overview
        7.1.2 Historical and Current Market Trends (2019-2024)
        7.1.3 Market Forecast (2025-2033)
    7.2    Retail Pharmacies
        7.2.1 Overview
        7.2.2 Historical and Current Market Trends (2019-2024)
        7.2.3 Market Forecast (2025-2033)
    7.3    Online Pharmacies
        7.3.1 Overview
        7.3.2 Historical and Current Market Trends (2019-2024)
        7.3.3 Market Forecast (2025-2033)
    7.4    Others
        7.4.1 Historical and Current Market Trends (2019-2024)
        7.4.2 Market Forecast (2025-2033) 
8   United States HIV Drugs Market – Breakup by Region
    8.1    Northeast
        8.1.1 Overview
        8.1.2 Historical and Current Market Trends (2019-2024)
        8.1.3 Market Breakup by Drug Class
        8.1.4 Market Breakup by Distribution Channel
        8.1.5 Key Players
        8.1.6 Market Forecast (2025-2033)
    8.2    Midwest
        8.2.1 Overview
        8.2.2 Historical and Current Market Trends (2019-2024)
        8.2.3 Market Breakup by Drug Class
        8.2.4 Market Breakup by Distribution Channel
        8.2.5 Key Players
        8.2.6 Market Forecast (2025-2033)
    8.3    South
        8.3.1 Overview
        8.3.2 Historical and Current Market Trends (2019-2024)
        8.3.3 Market Breakup by Drug Class
        8.3.4 Market Breakup by Distribution Channel
        8.3.5 Key Players
        8.3.6 Market Forecast (2025-2033)
   8.4    West
        8.4.1 Overview
        8.4.2 Historical and Current Market Trends (2019-2024)
        8.4.3 Market Breakup by Drug Class
        8.4.4 Market Breakup by Distribution Channel
        8.4.5 Key Players
        8.4.6 Market Forecast (2025-2033)
9   United States HIV Drugs Market – Competitive Landscape
    9.1    Overview
    9.2    Market Structure
    9.3    Market Player Positioning
    9.4    Top Winning Strategies
    9.5    Competitive Dashboard
    9.6    Company Evaluation Quadrant
10  Profiles of Key Players
    10.1    Company A
        10.1.1 Business Overview
        10.1.2 Product Portfolio
        10.1.3 Business Strategies
        10.1.4 SWOT Analysis
        10.1.5 Major News and Events
    10.2    Company B
        10.2.1 Business Overview
        10.2.2 Product Portfolio
        10.2.3 Business Strategies
        10.2.4 SWOT Analysis
        10.2.5 Major News and Events
    10.3    Company C
        10.3.1 Business Overview
        10.3.2 Product Portfolio
        10.3.3 Business Strategies
        10.3.4 SWOT Analysis
        10.3.5 Major News and Events
    10.4    Company D 
        10.4.1 Business Overview
        10.4.2 Product Portfolio
        10.4.3 Business Strategies
        10.4.4 SWOT Analysis
        10.4.5 Major News and Events
    10.5    Company E
        10.5.1 Business Overview
        10.5.2 Product Portfolio
        10.5.3 Business Strategies
        10.5.4 SWOT Analysis
        10.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

11  United States HIV Drugs Market - Industry Analysis
    11.1    Drivers, Restraints, and Opportunities
        11.1.1 Overview
        11.1.2 Drivers
        11.1.3 Restraints
        11.1.4 Opportunities
    11.2   Porters Five Forces Analysis
        11.2.1 Overview
        11.2.2 Bargaining Power of Buyers
        11.2.3 Bargaining Power of Suppliers
        11.2.4 Degree of Competition
        11.2.5 Threat of New Entrants
        11.2.6 Threat of Substitutes
    11.3    Value Chain Analysis
12  Appendix

United States HIV Drugs Market Report by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist, Fusion Inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials